Published in Clin Exp Immunol on April 01, 1977
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood (2008) 1.67
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther (2008) 1.44
Behavioral effects of A1- and A2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J Pharmacol Exp Ther (1991) 1.31
Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob Agents Chemother (1995) 1.21
Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment Pharmacol Ther (2009) 1.19
Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother (1999) 1.11
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer (2010) 1.10
Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect (2015) 1.08
Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother (1984) 1.07
The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions. Antimicrob Agents Chemother (1993) 1.06
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology (2009) 1.05
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther (2012) 1.03
Immunochemical characteristics of antibodies to DNA in patients with active systemic lupus erythematosus. Clin Exp Immunol (1979) 1.02
Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation. Br J Pharmacol (2004) 1.00
Combined immunosuppressive therapy with low dose FK506 and antimetabolites in rat allogeneic heart transplantation. Transplantation (1994) 0.98
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology (2011) 0.98
Analysis of the combined effect of two linear inhibitors on a single enzyme. Biochem J (1998) 0.97
Comparative in vitro Activity of Cefuroxime and its Interactions with Aminoglycoside Antibiotics. Proc R Soc Med (1977) 0.94
A proposed approach to study the toxicology of complex mixtures of petroleum products: the integrated use of QSAR, lumping analysis and PBPK/PD modeling. Environ Health Perspect (1997) 0.93
Drug interaction: focusing on response surface models. Korean J Anesthesiol (2010) 0.91
The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica (2013) 0.90
Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL. Leukemia (2013) 0.88
Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation. Br J Pharmacol (2007) 0.88
Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling. Antimicrob Agents Chemother (2001) 0.85
The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. Oncotarget (2017) 0.85
L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci. Infect Immun (2012) 0.85
Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res (2015) 0.85
Comparison of the inhibition by glucocorticosteroids and cyclosporin A of mitogen-stimulated human lymphocyte proliferation. Clin Exp Immunol (1981) 0.84
Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models. Philos Trans R Soc Lond B Biol Sci (2016) 0.84
Synergistic effects of locally administered cytostatic drugs and a surfactant on the development of delayed-type hypersensitivity to keyhole limpet haemocyanin in mice. Clin Exp Immunol (1989) 0.82
A pilot study to examine the effect of chronic treatment with immunosuppressive drugs on mucociliary clearance in a vagotomized murine model. PLoS One (2012) 0.82
Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev (2015) 0.80
Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158). J Clin Invest (1988) 0.80
Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer (2003) 0.80
Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro. Proc Natl Acad Sci U S A (1981) 0.79
A nonlinear isobologram model with Box-Cox transformation to both sides for chemical mixtures. Environ Health Perspect (1998) 0.79
Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol (1995) 0.78
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest (1987) 0.78
Chemopotentiation of mitomycin C cytotoxicity in vitro by platinum complexes. Br J Cancer (1985) 0.78
Differential sensitivity of RSVts (temperature-sensitive Rous-sarcoma virus)-infected rat kidney cells to nucleoside antibiotics at permissive and non-permissive temperatures. Biochem J (1985) 0.78
Assessment of non-linear combination effect terms for drug-drug interactions. J Pharmacokinet Pharmacodyn (2016) 0.77
The combined use of antilymphocyte serum and cyclophosphamide to suppress renal allograft rejection in the rat. Clin Exp Immunol (1979) 0.77
Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chem Biol (2014) 0.77
Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest (1993) 0.77
Immunodepression of thymus-independent response to dextran in mouse malaria. Clin Exp Immunol (1981) 0.76
Systems Pharmacology and Rational Polypharmacy: Nitric Oxide-Cyclic GMP Signaling Pathway as an Illustrative Example and Derivation of the General Case. PLoS Comput Biol (2016) 0.76
Synergistic interaction between selective drugs in cell populations models. PLoS One (2015) 0.75
An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. Front Pharmacol (2017) 0.75
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget (2015) 0.75
The mechanisms of inhibitory effects of liver extract on lymphocyte proliferation: II. Inhibition of DNA, RNA, and protein synthesis and their relationship to the effects of metabolic inhibitors. Clin Exp Immunol (1988) 0.75
The interaction of intrathecal neostigmine and N-cyclohexyladenosine on anti-allodynic effects in rats with a nerve ligation injury. Korean J Anesthesiol (2010) 0.75
MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations. Oncotarget (2017) 0.75
Synergistic reaction of silver nitrate, silver nanoparticles, and methylene blue against bacteria. Proc Natl Acad Sci U S A (2016) 0.75
Selenite Protection of Tellurite Toxicity Toward Escherichia coli. Front Mol Biosci (2015) 0.75
Suppressive drug combinations and their potential to combat antibiotic resistance. J Antibiot (Tokyo) (2017) 0.75
2-Deoxy-D-glucose Restore Glucocorticoid Sensitivity in Acute Lymphoblastic Leukemia via Modification of N-Linked Glycosylation in an Oxygen Tension-Independent Manner. Oxid Med Cell Longev (2017) 0.75
The scientific assessment of combined effects of risk factors: different approaches in experimental biosciences and epidemiology. Eur J Epidemiol (2010) 0.75
The problem of synergism and antagonism of combined drugs. Arzneimittelforschung (1953) 4.84
Quantitative studies on tissue transplantation immunity. 8. The effects of irradiation. Proc R Soc Lond B Biol Sci (1966) 1.89
Antagonisms and antagonists. Pharmacol Rev (1957) 1.46
Effects of roentgen radiation and cortisone on susceptibility of mice to Candida albicans. J Immunol (1957) 1.45
Dose-response curves for agents that impair cell reproductive integrity. A fundamental difference between dose-response curves of antimetabolites and those for radiation and alkylating agents. Br J Cancer (1969) 1.44
Cortisone and roentgen radiation in combination as synergistic agents for production of lethal infections. Proc Soc Exp Biol Med (1952) 1.34
Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone. Arthritis Rheum (1972) 1.27
Enhanced effects of prostaglandin E1 and dibutyryl cyclic AMP upon human lymphocytes in the presence of cortisol. J Clin Invest (1973) 1.18
THE RELATION OF RADIATION DOSAGE TO ENHANCEMENT, DEPRESSION, AND RECOVERY OF THE INITIAL FORSSMAN HEMOLYSIN RESPONSE IN RABBITS. J Infect Dis (1964) 1.16
THE EFFECT OF DELAYED ADMINISTRATION OF FOLINIC ACID ON IMMUNOLOGICAL INHIBITION BY METHOTREXATE. Immunology (1965) 1.13
The employment of combinations of drugs in the chemotherapy of neoplasia: a review. Cancer Res (1957) 1.12
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
Therapeutic studies in NZB-W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination. Arthritis Rheum (1972) 0.98
Survey of the current status of the clinical uses of antilymphocyte serum. Surg Gynecol Obstet (1976) 0.95
A study of combined treatment with chemical immunosuppressants and antilymphocytic serum to prolong skin allograft survival. Transplantation (1969) 0.93
Immunosuppression by pyrimidine nucleoside analogs. Biochem Pharmacol (1966) 0.92
Passive enhancement of kidney allografts: potentiation with antithymocyte serum. Transplantation (1972) 0.92
Synergism in immunosuppression. I. Effect of methylprednisolone, azathioprine, chlorambucil, and radiation on tetanus antitoxin production. Transplantation (1971) 0.91
Suppression of the immune response by drugs in combination. Proc Soc Exp Biol Med (1962) 0.91
Synergism of methotrexate with imuran and with 5-fluorouracil and their effects on hemolysin plaque-forming cell production in the mouse. Cancer Res (1974) 0.89
The effect of whole body x-irradiation of mice on immunity to tetanus toxoid. II. The delayed immune response to injections of tetanus toxoid. J Immunol (1956) 0.87
INDUCTION OF TOLERANCE WITH DISRUPTED ANTIGEN, IMURAN, AND SUBLETHAL IRRADIATION. Surg Forum (1964) 0.86
Enhanced suppression of experimental allergic encephalomyelitis by combination chemotherapy with duazomycin-A and 6-mercaptopurine. Proc Soc Exp Biol Med (1969) 0.86
Drug-induced tolerance: selective induction with immunosuppressive drugs and their synergistic interaction. Int Arch Allergy Appl Immunol (1975) 0.85
Cytarabine: cytocidal effect on normal and leukemic lymphocytes. Synergism with x rays and comparison with mechlorethamine. Exp Mol Pathol (1976) 0.84
The true mechanism of immunologic enhancement, deduced from studies of heart transplants in rats. Transplant Proc (1976) 0.83
Enhancement of skin grafts in the mouse. The combined used of specific and nonspecific immunosuppression. Transplantation (1975) 0.82
Combination chemotherapy for clinically established graft-versus-host disease in mice. Cancer Res (1973) 0.82
The effect of combined immunosuppressive agents and cell-free antigen on xenograft survival. Transplantation (1972) 0.82
ENHANCED SUPPRESSION OF THE SECONDARY IMMUNE RESPONSE BY COMBINATION OF 6-MERCAPTOPURINE DUAZOMYCIN A'. Nature (1963) 0.82
The effect of cysteine on the immunosuppressive activity of busulphan, cyclophosphamide and nitrogen mustard. Br J Cancer (1971) 0.82
Immunological enhancement. Transplant Proc (1971) 0.81
AZASERINE AND THIOPURINES. I. INHIBITION OF S-180 MOUSE TUMOR AND ANTIBODY SYNTHESIS. J Lab Clin Med (1964) 0.81
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin Exp Immunol (1971) 3.47
Postoperative depression of the lymphocyte response to phytohaemagglutinin. Lancet (1967) 2.57
Criteria for analyzing interactions between biologically active agents. Adv Cancer Res (1981) 2.49
The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06
In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer (1982) 1.82
Photodynamic destruction of human bladder carcinoma. Br J Cancer (1975) 1.55
Cerebral photosensitisation by haematoporphyrin derivative. Evidence for an endothelial site of action. Br J Cancer (1986) 1.53
Time-dependent immunosuppressive effects of anti-thymocyte serum. Nature (1967) 1.48
meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer (1986) 1.47
Dose-response curves for agents that impair cell reproductive integrity. A fundamental difference between dose-response curves of antimetabolites and those for radiation and alkylating agents. Br J Cancer (1969) 1.44
Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer (1991) 1.42
Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res (1974) 1.36
Depression of lymphocyte responses after surgical trauma. Br J Exp Pathol (1973) 1.29
Correlations between methods for measurement of synergy. J Infect Dis (1980) 1.29
The growth of human tumours in immunosuppressed mice and their response to chemotherapy. Br J Cancer (1974) 1.27
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents. Cancer Chemother Rep (1972) 1.26
Cell respiration as a requirement for antibody release in vitro. Nature (1968) 1.21
Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumour photosensitizers. Biochem J (1989) 1.19
Synergistic effect of cortisol and prostaglandin E2 on the PHA response. Relation to immunosuppression induced by trauma. Clin Exp Immunol (1976) 1.11
The therapeutic significance of the dose response curve for antilymphocytic serum. Transplantation (1971) 1.02
The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide. Clin Exp Immunol (1973) 1.01
Immunosuppression by L-asparaginase. Nature (1970) 0.99
The relation between the physico-chemical properties and immunosuppressive effects of an homologous series of sulphonic acid esters. Immunology (1967) 0.97
Effects of L-asparaginase on lymphocyte-target cell reactions in vitro. Nature (1970) 0.95
Synergy with double and triple antibiotic combinations compared. J Antimicrob Chemother (1983) 0.95
The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice. Br J Cancer (1971) 0.95
Wavelength and light-dose dependence in tumour phototherapy with haematoporphyrin derivative. Br J Cancer (1985) 0.94
Immunosuppressive agents: the design of selective therapeutic schedules. Antibiot Chemother (1969) 0.93
The rabbit VX2 tumour as a model for carcinomas of the tongue and larynx. Acta Otolaryngol (1989) 0.91
Synergy assessment with growth curves. J Infect Dis (1984) 0.90
Radiosensitivity of immunologically activated cells. Nature (1966) 0.89
Minor synergy and antagonism may be clinically important. J Antimicrob Chemother (1987) 0.88
Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. Transplantation (1975) 0.87
HPD - a study of its components and their properties. Adv Exp Med Biol (1983) 0.87
The localization of haemolytic antibody in sections of lymphoid organs: an improved method. Immunology (1970) 0.84
Synergy and antagonism are not synonymous with therapeutic advantage and disadvantage. J Antimicrob Chemother (1988) 0.84
Role of mitosis and mitotic inhibition in the immunosuppressive action of thioguanine. Nature (1966) 0.83
Consequences of synergy between environmental carcinogens. Environ Res (1985) 0.82
Protective effects of a novel perfluorochemical emulsion in photodynamic therapy. Biomater Artif Cells Immobilization Biotechnol (1992) 0.82
The effect of cysteine on the immunosuppressive activity of busulphan, cyclophosphamide and nitrogen mustard. Br J Cancer (1971) 0.82
Time-dependence and selectivity of immunosuppressive agents. Immunology (1979) 0.82
Effect of cyclophosphamide on the homograft response in the guinea pig. Transplantation (1965) 0.81
Effect of some metabolic inhibitors on plaque formation in Jerne plates. Nature (1967) 0.81
Transplantation and immunosuppression. Mod Trends Immunol (1967) 0.81
The mode of action of cytotoxic drugs. Proc R Soc Med (1970) 0.80
Differential asparaginase sensitivity of T-cell and B-cell responses. Clin Exp Immunol (1973) 0.80
Porphyrin sensitizers in tumour phototherapy. Novel sensitizers of the chlorin and bacteriochlorin class with amphiphilic properties. J Photochem Photobiol B (1990) 0.79
Research ethics and deception. Lancet (1980) 0.78
Letter: Predicting response of human cancer to chemotherapy. Lancet (1974) 0.78
Immunosuppressive agents: generation and consequences of differing dose-response curves. Proc R Soc Med (1972) 0.78
Immunosuppression by platinum diamines. Br J Cancer (1971) 0.77
Neutrophil function during chemotherapy for Hodgkin's disease. Br J Cancer (1981) 0.77
Intercellular immunological controls and modulation of cyclic AMP levels. Some doubts. Immunology (1976) 0.77
Photodynamic therapy of a mouse glioma: intracranial tumours are resistant while subcutaneous tumours are sensitive. Br J Cancer (1991) 0.77
Increased therapeutic efficiency of a lipid-soluble alkylating agent incorporated in liposomes. Br J Cancer (1982) 0.75
Autoimmunity and immunosuppression. Proc R Soc Med (1967) 0.75
Concepts for describing the interaction of two agents. Radiat Res (1991) 0.75
Dose-response curves for agents that impair cell reproductive integrity. The relation between dose-response curves and the design of selective regimens in cancer chemotherapy. Br J Cancer (1969) 0.75
Modes of action of immunosuppressive agents. Proc R Soc Med (1967) 0.75
Effect of L-asparaginase on germinal centre haemolysin. Nature (1971) 0.75
Intrathecal interferon, indomethacin, and multiple sclerosis. Lancet (1987) 0.75
Antagonism between radiosensitizing agents. Br J Radiol (1988) 0.75
The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil. Chemotherapy (1979) 0.75
Anti-HIV synergy between dextran sulphate and zidovudine. Lancet (1987) 0.75
Muscle damage and recovery in the rabbit tongue following photodynamic therapy with haematoporphyrin derivative. Acta Otolaryngol (1991) 0.75
Growth of human and rat tumours in immunosuppressed mice. J Pathol (1972) 0.75
Subcutaneous Corynebacterium parvum in bladder cancer: a controlled study of its immunological effects. Br J Urol (1979) 0.75
The last surviving cancer cell: the chances of killing it. Cancer Chemother Rep (1968) 0.75